Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Nova Laboratories LimitedPrivate | 1 asset: 1 approved | Approved assets only | None on record |
| 1 asset: 1 Ph 1 | XS-04Phase 1 · Acute Myeloid Leukemia | None on record | |
| 1 asset: 1 Ph 2 | NRD135S.E1Phase 2 · Diabetic Peripheral Neuropathic PainPartial signal | None on record | |
| 1 asset: 1 Ph 2 | KQ-2003Phase 1/2 · Multiple MyelomaWeak signal | 31 Dec 2027KQ-2003 · Phase 1 | |
NuPathe Inc.Private | 1 asset: 1 approved | Approved assets only | None on record |
 NurrOn PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | ATH-399A (HL192)Phase 1 · Parkinson's Disease | None on record |
 Nuvectis PharmaNVCT · Nasdaq | 1 asset: 1 Ph 1 | NXP900Phase 1 · Non-Small Cell Lung Cancer | Dec 2026NXP900 · Phase 1 |
 Nxera PharmaPrivate | 1 asset: 1 Ph 3 | NBI-1117568Phase 3 · SchizophreniaPartial signal | Oct 2027NBI-1117568 · Phase 3 |
 OBI Pharma, Inc4174 · TPEx | 1 asset: 1 Ph 2 | OBI-833Phase 2 · Non-Small Cell Lung Cancer | None on record |
 Obsidian Therapeutics, Inc.OBX · Nasdaq | 1 asset: 1 Ph 2 | OBX-115Phase 1/2 · Non-Small Cell Lung Cancer | 30 Jun 2029OBX-115 · Phase 1/2 |
 Odyssey TherapeuticsPrivate | 1 asset: 1 Ph 2 | OD-07656Phase 2 · Ulcerative ColitisWeak signal | None on record |
 Oils4CurePrivate | 1 asset: 1 Ph 3 | YCJ-01Phase 3 · Epilepsy | None on record |
 Oligomerix, IncPrivate | 1 asset: 1 Ph 1 | OLX-07010Phase 1 · Alzheimer's Disease | None on record |
 Onchilles Pharma IncPrivate | 1 asset: 1 Ph 2 | N17350Phase 1/2 · Non-Small Cell Lung Cancer | Jul 2028N17350 · Phase 1/2 |
 OncoPep, Inc.Private | 1 asset: 1 Ph 2 | PVX-410Phase 2 · Multiple MyelomaWeak signal | None on record |
 OncoResponse, Inc.Private | 1 asset: 1 Ph 2 | OR502Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 OncoVerity, Inc.Private | 1 asset: 1 Ph 2 | CusatuzumabPhase 2 · Acute Myeloid LeukemiaWeak signal | Jan 2027Cusatuzumab · Phase 2 |
 Oncolytics Biotech Inc.ONCY · Nasdaq | 1 asset: 1 Ph 3 | PelareorepPhase 3 · Advanced Metastatic Colorectal Cancer | 30 Jul 2027Pelareorep · Phase 1/2 |
 Oncopeptides AB (publ)ONCO · Nasdaq Stockholm | 1 asset: 1 approved | Approved assets only | None on record |
 One-carbon Therapeutics ABPrivate | 1 asset: 1 Ph 2 | TH9619Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026TH9619 · Phase 1/2 |
 Oneness Biotech4743 · TPEx | 1 asset: 1 Ph 2 | FB825Phase 2 · Atopic DermatitisWeak signal | 31 May 2027FB825 · Phase 2 |
 Opna Bio LLCPrivate | 1 asset: 1 Ph 1 | OPN-6602Phase 1 · Multiple Myeloma | None on record |
 OpsidioPrivate | 1 asset: 1 Ph 2 | OpSCFPhase 2 · Atopic DermatitisPartial signal | None on record |
 OptiNose, Inc.Private | 1 asset: 1 approved | Approved assets only | None on record |
 Opus Genetics, Inc.IRD · Nasdaq | 1 asset: 1 other | OPGx-LCA5Leber Congenital Amaurosis | None on record |
 OramedORMP · Nasdaq | 1 asset: 1 Ph 3 | ORMD-0801Phase 3 · Type 2 DiabetesPartial signal | 25 Apr 2027ORMD-0801 · Phase 3 |
 Orano Med Theranostics, SASPrivate | 1 asset: 1 Ph 1 | Pb-DOTAM-GRPR1Phase 1 · Non-Small Cell Lung Cancer | Jan 2027Pb-DOTAM-GRPR1 · Phase 1 |
| 1 asset: 1 Ph 2 | OriCAR-017Phase 1/2 · Multiple Myeloma | 30 Nov 2026OriCAR-017 · Phase 1/2 | |
 Oryzon Genomics, S.A.ORY · BME | 1 asset: 1 Ph 2 | IadademstatPhase 2 · Acute Myeloid LeukemiaWeak signal | None on record |
 Oscotec Inc.039200 · KOSDAQ | 1 asset: 1 Ph 1 | OCT-598Phase 1 · Non-Small Cell Lung Cancer | Dec 2027OCT-598 · Phase 1 |
 Oxford Vacmedix UK Ltd.Private | 1 asset: 1 Ph 1 | OVM-200Phase 1 · Non-Small Cell Lung Cancer | None on record |
 PAQ Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | PT0511Phase 1 · Non-Small Cell Lung Cancer | 18 Oct 2028PT0511 · Phase 1 |
 PDC*line Pharma SASPrivate | 1 asset: 1 Ph 2 | PDC*lung01Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 PMV Pharmaceuticals, IncPMVP · | 1 asset: 1 Ph 2 | rezatapoptPhase 1/2 · Non-Small Cell Lung Cancer | 15 Dec 2026rezatapopt · Phase 1/2 |
POZEN Inc.Private | 1 asset: 1 approved | Approved assets only | None on record |
 PRECISION BIOSCIENCES INCDTIL · Nasdaq | 1 asset: 1 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 1 Dec 2026Azercabtagene zapreleucel · Phase 1 |
 Pacylex PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | ZelenirstatPhase 1 · Acute Myeloid Leukemia | None on record |
 PadagisPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 Palisade BioPALI · Nasdaq | 1 asset: 1 Ph 2 | PALI-2108Phase 2 · Ulcerative ColitisPartial signal | Oct 2027PALI-2108 · Phase 2 |
 Parataxis Korea, Inc.288330 · KOSDAQ | 1 asset: 1 Ph 2 | BBT-207Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Partner Therapeutics, Inc.Private | 1 asset: 1 approved | Approved assets only | 31 Dec 2026Zenocutuzumab · Phase 2 |
 Pathalys PharmaPrivate | 1 asset: 1 Ph 3 | UpacicalcetPhase 3 · Chronic Kidney DiseasePartial signal | None on record |
 Peptron087010 · KOSDAQ | 1 asset: 1 Ph 2 | PT320Phase 2 · Parkinson's DiseasePartial signal | None on record |
| 1 asset: 1 Ph 1 | Leucettinib-21Phase 1 · Alzheimer's DiseasePartial signal | None on record | |
 Phanes TherapeuticsPrivate | 1 asset: 1 Ph 2 | PT199Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2027PT199 · Phase 1/2 |
 Pharma Two B Ltd.Private | 1 asset: 1 Ph 3 | P2B001Phase 3 · Parkinson's DiseaseReliable signal | None on record |
 PharmaEngine4162 · TPEx | 1 asset: 1 Ph 1 | PEP07Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026PEP07 · Phase 1 |
PharmacobioPrivate | 1 asset: 1 Ph 1 | DDN-A-0101Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 PharmacosmosPrivate | 1 asset: 1 approved | Approved assets only | 30 Apr 2027Ferric derisomaltose · Phase 3 |
 PharmatrophiXPrivate | 1 asset: 1 Ph 2 | LM11A-31Phase 1/2 · Alzheimer's DiseasePartial signal | None on record |
 Pheon TherapeuticsPrivate | 1 asset: 1 Ph 1 | PHN-012Phase 1 · Non-Small Cell Lung Cancer | Sep 2027PHN-012 · Phase 1 |
 Phrontline BiopharmaPrivate | 1 asset: 1 Ph 3 | TJ101Phase 3 · Non-Small Cell Lung Cancer | 30 Dec 2026TJ101 · Phase 1 |
 Pila PharmaPILA · Nasdaq First North | 1 asset: 1 Ph 2 | XEN-D0501Phase 2 · Type 2 DiabetesPartial signal | None on record |
 Pinnacle Biologics, Inc.Private | 1 asset: 1 approved | Approved assets only | None on record |
 Plexium, Inc.Private | 1 asset: 1 Ph 1 | PLX-61639Phase 1 · Non-Small Cell Lung Cancer | Dec 2029PLX-61639 · Phase 1 |
| 1 asset: 1 Ph 1 | PLN-101095Phase 1 · Non-Small Cell Lung Cancer | Jun 2030PLN-101095 · Phase 1 | |
 Pluri Inc.PLUR · Nasdaq | 1 asset: 1 Ph 3 | PLX-PADPhase 3 · Critical Limb Ischemia | None on record |
 Polaris Group6550 · TWSE | 1 asset: 1 Ph 3 | PegargiminasePhase 3 · Acute Myeloid LeukemiaWeak signal | 28 Feb 2027Pegargiminase · Phase 2 |
 Prestige Biopharma Limited950210 · KOSPI | 1 asset: 1 Ph 3 | HD204Phase 3 · Non-Small Cell Lung Cancer | None on record |
 Priavoid GmbHPrivate | 1 asset: 1 Ph 2 | PRI-002Phase 2 · Alzheimer's DiseasePartial signal | None on record |
 Prime Gene TherapeuticsPrivate | 1 asset: 1 Ph 3 | pumecitinibPhase 3 · Atopic Dermatitis | None on record |
| 1 asset: 1 Ph 1 | PLB-002Phase 1 · Non-Small Cell Lung Cancer | 30 Jun 2027PLB-002 · Phase 1 | |
 Priothera SASPrivate | 1 asset: 1 Ph 3 | mocravimodPhase 3 · Acute Myeloid Leukemia | May 2027mocravimod · Phase 3 |
 ProGen296160 · KONEX | 1 asset: 1 Ph 2 | PG-102Phase 2 · ObesityPartial signal | 1 Dec 2026PG-102 · Phase 1 |
 ProKidneyPROK · Nasdaq | 1 asset: 1 Ph 3 | RilparencelPhase 3 · Chronic Kidney DiseaseWeak signal | Dec 2029Rilparencel · Phase 3 |
 ProMIS Neurosciences, Inc.PMN · Nasdaq | 1 asset: 1 Ph 1 | PMN310Phase 1 · Alzheimer's Disease | Dec 2026PMN310 · Phase 1 |
 Promontory Therapeutics Inc.Private | 1 asset: 1 Ph 2 | PT-112Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record |
 Protara TherapeuticsTARA · Nasdaq | 1 asset: 1 Ph 3 | TARA-002Phase 3 · Non-Muscle Invasive Bladder Cancer | Dec 2026TARA-002 · Phase 2 |
 PulmatrixPULM · Nasdaq | 1 asset: 1 Ph 2 | PUR1900Phase 2 · Allergic Bronchopulmonary Aspergillosis | None on record |
 PulmovantPrivate | 1 asset: 1 Ph 3 | MosliciguatPhase 3 · Pulmonary Hypertension | Dec 2026Mosliciguat · Phase 2 |
 PurGenesis TechnologiesPrivate | 1 asset: 1 Ph 2 | PUR 0110Phase 2 · Atopic Dermatitis | None on record |
 PureIMSPrivate | 1 asset: 1 Ph 1 | Levodopa CyclopsPhase 1 · Parkinson's DiseasePartial signal | None on record |
 Pyxis OncologyPYXS · Nasdaq | 1 asset: 1 Ph 2 | PYX-201Phase 1/2 · Solid Tumors | 6 Dec 2027PYX-201 · Phase 1/2 |
 Q32 BioQTTB · Nasdaq | 1 asset: 1 Ph 2 | BempikibartPhase 2 · Atopic Dermatitis | None on record |
| 1 asset: 1 Ph 3 | Huaier GranulePhase 3 · Non-Small Cell Lung Cancer | None on record | |
| 1 asset: 1 Ph 2 | HS-IT101Phase 2 · Non-Small Cell Lung Cancer | 31 Dec 2027HS-IT101 · Phase 2 | |
 Quetzal TherapeuticsPrivate | 1 asset: 1 Ph 3 | QTX-2101Phase 3 | Mar 2027QTX-2101 · Phase 3 |
 Quince TherapeuticsQNCX · Nasdaq | 1 asset: 1 Ph 2 | LAM-001Phase 2 · Bronchiolitis Obliterans Syndrome | Mar 2028LAM-001 · Phase 2 |
 Rapa Therapeutics LLCPrivate | 1 asset: 1 Ph 2 | RAPA-201Phase 2 · Multiple MyelomaWeak signal | 1 Mar 2029RAPA-201 · Phase 2 |
 Rapport Therapeutics, Inc.RAPP · Nasdaq | 1 asset: 1 Ph 3 | RAP-219Phase 3 · EpilepsyWeak signal | 3 Feb 2028RAP-219 · Phase 2 |
 ReAlta Life SciencesPrivate | 1 asset: 1 Ph 2 | RLS-0071Phase 2 · Chronic Obstructive Pulmonary Disease | Dec 2026RLS-0071 · Phase 2 |
 RedCloud BioPrivate | 1 asset: 1 Ph 2 | H002Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record |
 RedHill BiopharmaRDHL · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
| 1 asset: 1 Ph 2 | RB-ADSCPhase 2 · Alzheimer's Disease | Sep 2028RB-ADSC · Phase 1 | |
 Remedy Plan, Inc.Private | 1 asset: 1 Ph 1 | RPT1GPhase 1 · Acute Myeloid Leukemia | 1 Dec 2028RPT1G · Phase 1 |
 Remix TherapeuticsPrivate | 1 asset: 1 Ph 2 | REM-422Phase 1/2 · Acute Myeloid Leukemia | 30 Sep 2027REM-422 · Phase 1/2 |
 Replicor Inc.Private | 1 asset: 1 Ph 2 | REP 2139-MgPhase 2 · Chronic Hepatitis B | None on record |
 Retension PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | RTN-001Phase 2 · Hypertension | Mar 2027RTN-001 · Phase 2 |
Rgene CorporationPrivate | 1 asset: 1 Ph 2 | BLEX 404Phase 1/2 · Non-Small Cell Lung Cancer | 30 Apr 2027BLEX 404 · Phase 2 |
 Rise TherapeuticsPrivate | 1 asset: 1 Ph 1 | R-3750Phase 1 · Ulcerative Colitis | 30 Apr 2028R-3750 · Phase 1 |
River 2 RenalPrivate | 1 asset: 1 Ph 2 | R2R01Phase 2 · Heart FailurePartial signal | 1 Apr 2027R2R01 · Phase 2 |
 Rivus PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | HU6Phase 2 · Heart FailurePartial signal | Feb 2027HU6 · Phase 2 |
 Rockwell MedicalRMTI · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 Rohto Pharmaceutical4527 · TSE | 1 asset: 1 Ph 2 | ADR-002KPhase 2 · Heart Failure | 30 Sep 2028ADR-002K · Phase 2 |
 Rondo TherapeuticsPrivate | 1 asset: 1 Ph 1 | RNDO-564Phase 1 · Non-Small Cell Lung Cancer | 28 Feb 2029RNDO-564 · Phase 1 |
 Ryvu Therapeutics SAPrivate | 1 asset: 1 Ph 2 | RVU120Phase 2 · Acute Myeloid LeukemiaWeak signal | Dec 2026RVU120 · Phase 2 |
S-Evans BiosciencesPrivate | 1 asset: 1 Ph 2 | Menstrual blood-derived mesenchymal stem cells (MenSCs)Phase 1/2 | None on record |
 SCM Lifescience298060 · KOSDAQ | 1 asset: 1 Ph 2 | SCM-AGHPhase 1/2 · Atopic DermatitisPartial signal | None on record |
 SDK TherapeuticsPrivate | 1 asset: 1 Ph 1 | SDK001Phase 1 · Acute Myeloid LeukemiaPartial signal | None on record |
 SFA TherapeuticsPrivate | 1 asset: 1 Ph 3 | SFA-002Phase 2/3 · Psoriasis | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).